Align Technology has delivered 3 consecutive quarterly earnings beats averaging roughly 10% above estimates and converts 125% of net income into free cash flow, but the stock is near its analyst consensus target with just 2% upside remaining and an unfavorable reward-to-risk ratio; elevated put-to-call activity and 80% product concentration in the clear aligner segment limit the near-term conviction case.
Thesis pillars
- Clear Aligner Product Concentration→Stable
- Consecutive Earnings Beat Streak→Stable
- Superior Free Cash Flow Conversion→Stable
- +1 more pillar — see the Why tab for full reasoning
Align Technology, Inc. (ALGN) Stock Analysis
Breakout setup · Catalyst-Driven edge
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $184.52 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Clear Aligner segment (80.0%).
Align Technology designs and manufactures Invisalign clear aligners (80% of 2025 worldwide net revenues) and iTero intraoral scanners plus exocad CAD/CAM software (the remaining 20%), sold globally to orthodontists, general dental practitioners, and dental laboratories. Over 22... Read more
Sell if holding. Analyst target reached at $184.52 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Clear Aligner segment (80.0%). Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Score 5.6/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 26d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and news legal. Suitability: aggressive.
About Align Technology, Inc.
About Align Technology, Inc.
Align Technology's Invisalign clear aligner system — FDA-cleared in 1998 and used in more than 22 million patient treatments globally — generated approximately 80% of the company's 2025 worldwide net revenues, with iTero intraoral scanners and exocad CAD/CAM software contributing the remaining 20%. The company serves orthodontists, general dental practitioners, DSOs, and dental laboratories through regional headquarters in Raleigh, Rotkreuz (Switzerland), and Singapore, with over 95% of prescription orders now submitted via digital scan.
Align Technology generates revenue through tiered Invisalign treatment packages — from limited-stage packages for minor corrections to multi-stage packages addressing complex malocclusion cases — plus Vivera retainers, iTero scanner hardware, software subscriptions, and exocad CAD/CAM licenses. Orthodontists and GPs must complete Invisalign training before prescribing, which reinforces adoption and creates friction for switching to competing products. Products are sold directly through a dedicated salesforce to practitioners, DSOs, and dental labs, with agents and distributors handling certain international markets. Revenue is sensitive to consumer discretionary spending because orthodontic treatment competes with lower-cost wires and brackets and is often treated as an elective procedure; uncertain economic outlooks in the United States, China, and European markets have historically reduced demand. China volume-based procurement programs and geographic mix shifts toward lower-priced regions may weigh on average selling prices. The company faces growing competition from DTC clear aligner providers requiring little to no in-office care, white-label third-party manufacturers, and doctors or DSOs producing aligners in-house.
Show full overview
Align Technology estimates its Invisalign System captures about 10% of the approximately 22 million annual orthodontic case starts through orthodontists globally, suggesting substantial untapped share of the wires-and-brackets market. However, the 10-K acknowledges that a meaningful segment of dental professionals believes Invisalign treatment is appropriate for only a limited percentage of patients, constraining physician-side adoption. The company manufactures clear aligners in a facility in Mexico and ships them to the United States primarily for domestic customers, exposing production costs to potential Section 232 trade investigations into medical equipment and device imports.
See also: Healthcare · Medical Instruments & Supplies
From Align Technology, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-06Recent Developments — Align Technology, Inc.
Latest news
- NEWS Align Technology (ALGN) Moves Forward with $200 Million Stock Bu - GuruFocus — GuruFocus positive
- NEWS Align Technology (ALGN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance — Yahoo Finance neutral
- NEWS (ALGN) Align Technology, Inc. Expects Q2 Revenue Range $1.04B - $1.06B - marketscreener.com — marketscreener.com positive
- NEWS Earnings Flash (ALGN) Align Technology, Inc. Posts Q1 Adjusted EPS $2.58 per Share, vs. FactSet Est of $2.30 - marketscr — marketscreener.com positive
- NEWS Align Technology (NASDAQ:ALGN) Surprises With Q1 CY2026 Sales - StockStory — StockStory positive
Generated 2026-07-06T04:40:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductClear Aligner segment80%10-K Item 1: 'For the year ended December 31, 2025, Clear Aligner net revenues represented approximately 80% of worldwide net revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $184.52 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Clear Aligner segment (80.0%). Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Prior stop was $171.60. Score 5.6/10, moderate confidence.
Take-profit target: $182.79 (-0.9% upside). Prior stop was $171.60. Stop-loss: $171.60.
Concentration risk — Product: Clear Aligner segment (80.0%); Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.8): -1.5.
Align Technology, Inc. trades at a P/E of 31.1 (forward 14.9). TrendMatrix value score: 6.0/10. Verdict: Sell.
24 analysts cover ALGN with a consensus score of 4.0/5. Average price target: $209.
What does Align Technology, Inc. do?Align Technology designs and manufactures Invisalign clear aligners (80% of 2025 worldwide net revenues) and iTero...
Align Technology designs and manufactures Invisalign clear aligners (80% of 2025 worldwide net revenues) and iTero intraoral scanners plus exocad CAD/CAM software (the remaining 20%), sold globally to orthodontists, general dental practitioners, and dental laboratories. Over 22 million patients have been treated with the Invisalign System since 1998 FDA clearance.